Loading...
Updated clinical practice guidelines for the management of adult diffuse gliomas
Зохиогч
Jiang, Tao
Nam, Do-Hyun
Ram, Zvi
Poo, Wai-Sang
Wang, Jiguang
Mao, Ying
Ma, Wenbin
Mao, Qing
You, Yongping
Jiang, Chuanlu
Yang, Xuejun
Tergaonkar, Vinay
Zhang, Wei
Wang, Zheng
Kang, Chunsheng
Qiu, Xiaoguang
Li, Shaowu
Chen, Ling
Li, Xuejun
Liu, Zhixiong
Bai, Hongmin
Yao, Yu
Li, Shouwei
Wu, Anhua
Mou, Yonggao
Sai, Ke
Li, Guilin
Wei, Xinting
Liu, Xianzhi
Zhang, Zhiwen
Dai, Yiwu
Lv, Shengqing
Wang, Liang
Lin, Zhixiong
Dong, Jun
Xu, Guozheng
Ma, Xiaodong
Yu, Rutong
Kang, Dezhi
Liu, Yanhui
Li, Gang
Zhang, Shizhong
Qu, Yan
Wang, Yang
Zhang, Chuanbao
Chen, Baoshi
You, Gan
Wang, Yongzhi
Wang, Yinyan
Bao, Zhaoshi
Fan, Xing
Liu, Xing
Zhao, Zheng
Li, Yiming
Wang, Zhiliang
Li, Guanzhang
Fang, Shengyu
Liu, Yanwei
Shan, Xia
Liu, Yuqing
Chai, Ruichao
Hu, Huimin
Chen, Jing
Yan, Wei
Cai, Jinquan
Wang, Yu
Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNOChina), Chinese Brain Cancer Association (CBCA), Chinese Glioma Genome Atlas (CGGA), Asian Glioma Genome Atlas (AGGA) network
Он
2026 оны гуравдугаар сар
Төрөл
journal article
Journal
Cancer letters
Volume
640
Start Page
218185
ISSN
1872-7980
Хураангуй
It has been five years since the last version of the clinical practice guidelines for the management of adult diffuse gliomas was published by the Asian Glioma Genome Atlas (AGGA). Significant progress and revisions have occurred in the diagnosis and treatment of adult diffuse gliomas in recent years. In response to these updates, the joint guideline committee of the Chinese Glioma Cooperative Group (CGCG), the Society for Neuro-Oncology of China (SNO-China), and the Chinese Brain Cancer Association (CBCA) has revised the clinical practice guidelines. This updated guideline emphasizes molecular and pathological diagnostics, as well as the primary treatment modalities of surgery, radiotherapy, chemotherapy, and targeted therapy. Additionally, we have incorporated findings from recent clinical trials of new therapies to align with cutting-edge treatment strategies. This guideline is designed to serve as a practical resource for all professionals involved in managing adult diffuse glioma patients, while also providing valuable information for insurance companies and other institutions responsible for regulating cancer care costs in China and beyond.
